Open Respiratory Archives最新文献

{"title":"High Ferritin Predicts Mortality in Patients With Interstitial Pneumonia and an Underlying Autoimmune Disease","authors":"María Jesús Rodríguez-Nieto ,&nbsp;Fredeswinda Romero-Bueno ,&nbsp;Lydia Abásolo ,&nbsp;María Carmen Vegas Sánchez ,&nbsp;Begoña López-Botet Zulueta ,&nbsp;Olga Sánchez-Pernaute ,&nbsp;the NEREA Autoimmune ILD Study Group","doi":"10.1016/j.opresp.2025.100455","DOIUrl":"10.1016/j.opresp.2025.100455","url":null,"abstract":"<div><h3>Purpose</h3><div>To identify early predictive markers in patients with chronic interstitial pneumonia (IP) associated with an underlying autoimmune disease (AIP), aiming to facilitate personalized follow-up and treatment.</div></div><div><h3>Methods</h3><div>We assessed the predictive value of process and host factors on mortality in a cohort of 124 patients (86 women) with autoimmune interstitial pneumonia (AIP). This cohort comprised 66 cases of connective tissue disease-associated interstitial pneumonia (CTD-IP), 40 patients with interstitial pneumonia with autoimmune features (IPAF), and 18 patients with undifferentiated autoimmune IP. All patients had a minimum follow-up of 2 years or a fatal outcome. We included demographics, clinical diagnostic subgroups, specific antibodies, morphological patterns, and relevant laboratory tests in our analysis. For the bivariate analysis, we employed Student's <em>t</em>-test, Fisher's exact test, and survival techniques. Prediction models for death risk were developed using logistic regression.</div></div><div><h3>Results</h3><div>During the follow-up period, there were 29 deaths, resulting in an incidence rate of 3.09 per 100 patient-year. Factors associated with an increased risk of death included older age at diagnosis, cardio-respiratory comorbidities, and a simultaneous onset of intersticial pneumonia and systemic manifestations. In contrast, clinical diagnosis and radiographic patterns did not show a significant association with mortality risk. Additionally, elevated levels of lactate dehydrogenase, sedimentation rate, C-reactive protein, and ferritin were significantly linked to fatal outcomes. Among these, ferritin emerged as the most potent predictor in the multivariate model, with an odds ratio of 5.9 (<em>p</em> <!-->=<!--> <!-->0.002).</div></div><div><h3>Conclusion</h3><div>Our data emphasize the importance of monitoring inflammatory markers, particularly ferritin levels, to assess prognosis across various subtypes of autoimmune intersticial pneumonia.</div></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"7 3","pages":"Article 100455"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145044363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Dynamics in the Airway Bacterial Profile in Bronchiectasis","authors":"Grace Oscullo ,&nbsp;Jose Daniel Gomez-Olivas ,&nbsp;Miguel Ángel Martinez-García","doi":"10.1016/j.opresp.2025.100468","DOIUrl":"10.1016/j.opresp.2025.100468","url":null,"abstract":"","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"7 3","pages":"Article 100468"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144721478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary Arteriovenous Malformations and Pregnancy: A Case Report","authors":"Jimmy Icaza Vera ,&nbsp;Javier Alfayate Sánchez ,&nbsp;Marcel José Rodríguez Guzmán","doi":"10.1016/j.opresp.2025.100454","DOIUrl":"10.1016/j.opresp.2025.100454","url":null,"abstract":"","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"7 3","pages":"Article 100454"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary Alveolar Microlithiasis: Case Report","authors":"Alexander Ali Jiménez Romero ,&nbsp;Rocio Hernandez Caler ,&nbsp;Jose Javier Martinez Garceran ,&nbsp;Soledad Blasco Muñoz","doi":"10.1016/j.opresp.2025.100476","DOIUrl":"10.1016/j.opresp.2025.100476","url":null,"abstract":"","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"7 3","pages":"Article 100476"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144922743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tracheal–Bronchial Leishmaniasis: A Rare Mucosal Presentation in Three Cases From a Single Center in Spain","authors":"Carmen Lores Benavente ,&nbsp;Domingo Madera Hernández ,&nbsp;Rosa López Lisbona ,&nbsp;Núria Sabé ,&nbsp;Núria Baixeras ,&nbsp;Rosana Blavia ,&nbsp;Mariana Mercedes Muñoz Esquerre","doi":"10.1016/j.opresp.2025.100465","DOIUrl":"10.1016/j.opresp.2025.100465","url":null,"abstract":"","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"7 3","pages":"Article 100465"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term Tolerance to Inhaled Antibiotics in Patients With Bronchial Infection not Associated With Cystic Fibrosis","authors":"Luis Máiz ,&nbsp;Rosa Nieto ,&nbsp;Diego Durán ,&nbsp;José Máiz ,&nbsp;Gabriel Ruiz-Calvo ,&nbsp;Alfonso Muriel ,&nbsp;Esther Barbero ,&nbsp;Manuel Vélez-Díaz-Pallarés ,&nbsp;Raquel Morillo","doi":"10.1016/j.opresp.2025.100460","DOIUrl":"10.1016/j.opresp.2025.100460","url":null,"abstract":"<div><h3>Introduction</h3><div>The use of intravenous antibiotic formulations delivered by inhalation is controversial. Tolerance can be an issue and some treatment guidelines discourage this route of administration if the same antibiotic is available in an inhalation formulation.</div></div><div><h3>Material and methods</h3><div>This was a retrospective, observational, single-center study comparing tolerance to three antibiotics delivered by nebulization (intravenous formulations of ampicillin and gentamicin, and an inhalation formulation of colistimethate sodium) in patients with bronchial infection (BI), chronic bronchial infection (CBI), and/or recurrent respiratory infections. The study also aimed to identify factors potentially associated with tolerability.</div></div><div><h3>Results</h3><div>A total of 330 antibiotic tolerance tests were performed in 135 patients (mean age 68 years; 48.9% female; mean post-bronchodilator FEV₁% predicted 65.9%). Of these patients, 62.2% had bronchiectasis and 39.3% had chronic obstructive pulmonary disease (COPD). The best tolerated antibiotic was colistimethate. Overall, 89.6% of colistimethate doses were tolerated, compared to 69.5% of inhaled gentamicin doses (<em>P</em> <!-->&lt;<!--> <!-->0.001) and 69.1% of ampicillin doses (<em>P</em> <!-->&lt;<!--> <!-->0.001). Compared with colistimethate administration, the odds of intolerance were 5.69 times higher for gentamicin (<em>P</em> <!-->&lt;<!--> <!-->0.001) and 6.21 times higher for ampicillin (<em>P</em> <!-->&lt;<!--> <!-->0.001). In the univariate analysis, factors that may have been associated with antibiotic intolerance included smoking habit, worse post-bronchodilator FEV₁% predicted and a diagnosis of COPD. In the multivariate analysis, after adjustment for antibiotic type, smoking habit, post-bronchodilator FEV₁ and COPD diagnosis, the only factor influencing tolerance was the type of antibiotic used.</div></div><div><h3>Conclusion</h3><div>In patients with BI and/or CBI and/or recurrent respiratory infections, inhaled sodium colistimethate is significantly better tolerated than intravenous formulations of gentamicin and ampicillin for the inhalation route. The only factor influencing tolerance is the type of antibiotic used.</div></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"7 3","pages":"Article 100460"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144623851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design of a Tool to Classify Chronic Cough According to its Severity: Cough Severity Questionnaire (CSQ)","authors":"Esther Palones ,&nbsp;Ebymar Arismendi ,&nbsp;Abigail Macías ,&nbsp;Carlos Martínez ,&nbsp;Mariana Muñoz-Esquerre ,&nbsp;Ana Sogo Sagardía ,&nbsp;Eduardo Valverde ,&nbsp;Eduardo Vélez-Segovia ,&nbsp;Astrid Crespo-Lessmann","doi":"10.1016/j.opresp.2025.100464","DOIUrl":"10.1016/j.opresp.2025.100464","url":null,"abstract":"","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"7 3","pages":"Article 100464"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mepolizumab for Eosinophilic COPD: What Matinee Adds to COPD Management?","authors":"Isabel Maria Alcázar-Martínez ,&nbsp;Pedro Jose Romero-Palacios ,&nbsp;Bernardino Alcázar-Navarrete","doi":"10.1016/j.opresp.2025.100475","DOIUrl":"10.1016/j.opresp.2025.100475","url":null,"abstract":"","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"7 3","pages":"Article 100475"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144922744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delphi Consensus on the Management of COPD Exacerbation Syndrome in Inpatient and Outpatient Settings","authors":"Javier de Miguel Díez ,&nbsp;Juan Marco Figueira Gonçalves ,&nbsp;Carlota Rodríguez García ,&nbsp;Carlos Antonio Amado Diago ,&nbsp;Miriam Barrecheguren ,&nbsp;Bernardino Alcázar Navarrete","doi":"10.1016/j.opresp.2025.100458","DOIUrl":"10.1016/j.opresp.2025.100458","url":null,"abstract":"<div><h3>Introduction</h3><div>COPD is a respiratory condition characterized by chronic airflow limitation. Exacerbations are an acute worsening of the symptoms. The objective of this study was to achieve a consensus on the management of COPD exacerbation syndrome in inpatient and outpatient settings.</div></div><div><h3>Material and methods</h3><div>A committee of experts developed a 60-item questionnaire to be agreed by a panel of experts, categorized into seven sections.</div></div><div><h3>Results</h3><div>After two rounds, consensus was reached on 81.7% of the items. Strong consensus (more than 85%) was reached on the importance of implementing protocols to help patients with exacerbations in both outpatient (92.7%) and inpatient (94.3%) settings. Regarding the criteria for hospitalization due to an exacerbation, respondents agreed that they are clearly defined (75.5%). Regarding bronchodilator use for CES, the only statement that did not achieve agreement was whether there are clinical differences between the use of nebulized rescue bronchodilators and pressurized metered-dose inhalers (pMDIs) with a spacer. Regarding CES treatment in the outpatient setting, consensus was reached for almost all statements, in contrast to what was found for inpatient treatment. Respondents disagreed with the statement that the use of SABA should be accompanied by the discontinuation of LAMAs or LABAs, with or without corticosteroids (74.8%). In the context of a COPD exacerbation requiring hospitalization, inhaled triple therapy should be prescribed (regardless of prior treatment) in the absence of contraindications. Regarding post-discharge protocols and rehabilitation, respondents reached consensus on all statements.</div></div><div><h3>Conclusions</h3><div>This Delphi consensus study provides valuable insights into the current management of CES, highlighting several areas where consensus remains elusive.</div></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"7 4","pages":"Article 100458"},"PeriodicalIF":0.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144670417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Key Updates in the 2025 Spanish Asthma Guidelines (GEMA 5.5)","authors":"Carlos Almonacid ,&nbsp;Marina Blanco ,&nbsp;Jorge Ferreira ,&nbsp;Gabriel García ,&nbsp;Ana Morete ,&nbsp;Santiago Quirce ,&nbsp;Gregorio Soto-Campos ,&nbsp;Vicente Plaza","doi":"10.1016/j.opresp.2025.100453","DOIUrl":"10.1016/j.opresp.2025.100453","url":null,"abstract":"","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"7 3","pages":"Article 100453"},"PeriodicalIF":0.0,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144491314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}